Research programme: antibody therapeutics - AnaptysBio

Drug Profile

Research programme: antibody therapeutics - AnaptysBio

Alternative Names: ANA 02; ANA 04; ANA 505; ANB 004; ANB 012

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AnaptysBio
  • Developer AnaptysBio; TESARO
  • Class Antibodies; Antifibrotics; Antineoplastics; Antipsoriatics; Bispecific antibodies; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action CD223 antigen inhibitors; Checkpoint kinase inhibitors; HAVCR2 protein inhibitors; Immunomodulators; Interleukin 36 receptor antagonists; Interleukin-17 inhibitors; Membrane protein inhibitors; Nerve growth factor inhibitors; PDCD 1 protein inhibitors; Type-II-B activin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pustular psoriasis
  • Research Cancer
  • No development reported Autoimmune disorders; Fibrosis; Inflammation; Muscular atrophy; Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for research development in Fibrosis in USA (Parenteral)
  • 27 Apr 2017 TESARO plans a label expansion trial in multiple Cancers (Combination therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top